Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1843-1847

  Curtis, Jeffrey R ^a,b   Xie, Fenglong ^a   Yun, Huifeng ^a,b   Bernatsky, Sasha ^c   Winthrop, Kevin L ^d  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Infections; Rheumatoid Arthritis; Vaccination

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; AGE; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMPARATIVE STUDY; HERPESVIRIDAE INFECTIONS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; VIROLOGY;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRIDAE INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PIPERIDINES; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; PYRROLES; RISK FACTORS; SEX FACTORS;

EID: 84965060726     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209131     Document Type: Article

References (20)

1. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
2. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
3. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2675-84.
4. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:353-61.
5. Yun H, Yang S, Chen J, et al. Risk of Herpes Zoster in Auto-immune and Inflammatory diseases: Implications for Vaccination. Arthritis Rheumatol 2016. [Epub ahead of print 18 Mar 2016]. doi:10.1002/art.39670.
6. Burgos R, Ordoñez G, Vázquez-Mellado J, et al. Occasional presence of herpes viruses in synovial fluid and blood from patients with rheumatoid arthritis and axial spondyloarthritis. Clin Rheumatol 2015;34:1681-6.
7. Ayanian JZ, Landon BE, Zaslavsky AM, et al. Racial and ethnic differences in use of mammography between Medicare Advantage and traditional Medicare. J Natl Cancer Inst 2013;105:1891-6.
8. Bynum J, Song Y, Fisher E. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare. J Am Geriatr Soc 2010;58:674-80.
9. Hansen L, CS Health Research Data for the Real World: The Marketscan Databases. 2011. http://truvenhealth.com/portals/0/assets/PH-11238-0612-TEMP-MarketScan-WP-FINAL.pdf (accessed 18 Feb 2016).
10. Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
11. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9.
12. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9.
13. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
14. White H. A heteroskedasticity-consistent covariace matrix estimator and a direct test for heteroscedasticity. Econometrica 1980;48:817-30.
15. Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) 2015;67:731-6.
16. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-44.
17. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012;64: 1790-8.
18. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004;24:439-54.
19. Jung CW, Shih LY, Xiao Z, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma 2015;56:2067-74.
20. Pappas DA, et al. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken) 2015; 67:1671-8.